Journal International Journal Nanomedicine Article Designation Original Research Year 2017 Volume 12 Running head verso Marcianes et al Running head recto Gatifloxacin NPs CNS tuberculosis DOI httpdxdoiorg102147IJNS130908 International Journal Nanomedicine Open access Full Text article Dovepress open access scientific medical research O rIg I Na l s e r c h Surfacemodified gatifloxacin nanoparticles potential treating central nervous tuberculosis Patricia Marcianes1 Sofia Negro12 luis garcíagarcía 3 consuelo Montejo 4 emilia Barcia 12 ana Fernándezcarballido 12 1Department Pharmaceutics School Pharmacy University Complutense Madrid Madrid spain 2Institute Pharmaceutical Technology University complutense Madrid Madrid spain 3Multidisciplinary Institute Cerebral Cartography University complutense Madrid Madrid spain 4Department Pharmaceutical Health Sciences School Pharmacy University CEUSan Pablo Spain Correspondence Sofia Negro Departamento Farmacia y Tecnología Farmacéutica Facultad Farmacia Universidad Complutense Madrid Plaza Ramón y Cajal Madrid 28040 Spain Tel 34 91 394 1741 Fax 34 91 394 1736 email sonealucmes Abstract A new nanocarrier developed passage gatifloxacin bloodbrain barrier treat central nervous tuberculosis Gatifloxacin nanoparticles prepared nanoprecipitation polylacticcoglycolic acid PLGA 502 polysorbate 80 Labrafil surface modifiers The evaluation vivo bloodbrain barrier transport carried male Wistar rats rhodamineloaded PLGA nanoparticles prepared surface modifiers At 30 60 minutes administration nanoparticle biodistribution brain hippocampus cortex lungs liver studied The results obtained cerebral cortex hippocampus showed functionalization rhodamine nanoparticles significantly increased passage central nervous At 60 minutes rhodamine concentrations decreased lungs liver high cerebral cortex To distinguish effect surfactants gatifloxacin loaded PLGA nanoparticles prepared The best results corresponded formulation prepared polysorbate 80 regard encapsulation efficiency 282 particle size 1765 nm ζpotential 201 mV resulting promising drug delivery treat cerebral tuberculosis Keywords polysorbate 80 Labrafil gatifloxacin nanoparticles targeting bloodbrain barrier brain delivery Introduction Tuberculosis tubercle bacillus TB pathology present mainly lungs develop extrapulmonary infection central nervous CNS body In years epidemiology TB altered emergence HIV infection TB CNS represents 1 disease worldwide devastating fatal affects primarily young children The mortality extraordinarily high severe neurological sequelae Two major forms CNS TB include meningitis accounts 051 TB disease intracranial tuberculomas represent 40 brain tumors1 The bloodbrain barrier BBB effective barrier drugs hindering effective treatment case CNS TB The possibility crossing barrier restrictive absence paracellular transcellular channels substances able barrier means diffusion receptor carriermediated transport Moreover luminal abluminal membranes brain capillary endothelium separated 200 nm endothelial cytoplasm limiting passage drugs Therefore BBB protects brain submit manuscript wwwdovepresscom Dovepress httpdxdoiorg102147IJNS130908 International Journal Nanomedicine 201712 19591968 1959 2017 Marcianes et al This work published licensed Dove Medical Press Limited The terms license available httpswwwdovepresscomtermsphp incorporate Creative Commons Attribution Non Commercial unported v30 License httpcreativecommonsorglicensesbync30 By accessing work accept Terms Noncommercial uses work permitted permission Dove Medical Press Limited provided work properly attributed For permission commercial use work paragraphs 42 5 Terms httpswwwdovepresscomtermsphp Marcianes et al Dovepress toxic substances restricts entrance therapeuti cally important drugs2 Treatment CNS TB complex increasing incidence multidrugresistant MDR extensively DR totally DR strains Mycobacterium tuberculosis MDRTB defined TB caused M tuberculosis resistant isoniazid rifampicin Resistance phenomena represent major threat effective therapeu tic control TB For instance 2014 approximately 480000 cases MDRTB described 33 corresponded new cases 20 previously treated cases3 One mechanisms involved MDRTB drug efflux mediated permeability Pglycoprotein Pgp prevents cellular drug accumulation brain reducing efficacy treatment Efforts reduce MDR studied nonionic surfactants Tween Pluronic dαtocopheryl polyethylene glycol PEG Brij potential actions reducing cellular drug efflux4 Newgeneration fluoroquinolones secondline antiTB drugs proven efficient treating MDRTB Within quinolones gatifloxacin Gat new compound twice active levofloxacin exhibits lower access CNS56 Gat high low incidence drug resistance substrate Pgp78 For reason administration Gat agents able inhibit Pgp efflux use therapeutic systems able increase access CNS benefit improvement therapeutic outcome Gat therapy Nanotechnology promising strategy target ing CNS diseases TB In fact impor tant challenges pharmaceutical technology develop efficient transport systems able carry drugs BBB Several studies shown polylacticcoglycolic acid PLGA nanoparticles NPs sizes 250 nm cross BBB911 However percentage particles able pass barrier low To overcome problem approaches investigation coating NPs sur factants surfacemodifier agents specific ligands case polysorbate 80 NPs1213 Moreover therapeutic NPs emerged innovative promising option target Pgpmediated multidrug resistance14 Taking consideration developed Gat loaded PLGA NPs able cross BBB treatment CNS TB Moreover prepared evaluated vivo PLGA NPs functionalized different surfactants polysorbate 80 Labrafil M1944CS surface modifiers order evaluate passage BBB The biodistribution NPs studied liver lungs representative organs CNS TB Materials methods Rhodamine Rh123 supplied SigmaAldrich St Louis MO USA Gat sesquihydrate 1cyclopropyl 6fluoro8methoxy73methylpiperazin1yl4oxo14 dihydroquinoline3carboxylic acid sesquihydrate Santa Cruz Biotechnology Dallas TX USA PLGA ratio 5050 PLGA Resomer RG 502 purchased Evonik Essen Germany Polysorbate 80 obtained PanReac Barcelona Spain Labrafil M 1944 CS PEG5 oleate FDA IIG supplied Gattefossé Lyon France Polyvinyl alcohol PVA molecular weight 3000070000 Da obtained SigmaAldrich Oth ers reagents analytical grade provided Merck Darmstadt Germany Distilled deionized water MilliQ EMD Millipore Billerica MA USA preparation buffers solutions Preparation characterization NPs Rhodamineloaded PLGA NPs Rhloaded PLGA NPs NPR1 Table 1 prepared nanoprecipitation acetonewater Briefly 50 mg PLGA 25 mg Rh dissolved 4 mL acetone mixed vortexing This mixture added dropwise 12 mL 1 PVA continuous stirring 15 minutes The resulting suspension evaporated rotary evaporator RotavaporR Büchi Labortechnik AG Flawil Switzerland remove acetone completely 2 hours 25C 70 mbar The NP suspension obtained washed distilled water times cen trifuged Avanti J301 Beckman Coulter Brea CA USA 15000 rpm 30 minutes remove PVA Finally dispersed solution freezedried 24 hours sucrose Table 1 Nanoparticle formulations developed Formulation Rhodamine NPr1 NPr2 NPr3 NPB1 NPB2 NPB3 NPg1 NPg2 NPg3 mg 25 25 25 Gatifloxacin mg Polysorbate 80 Labrafil mg 5 5 5 1 1 1 35 35 35 1960 submit manuscript wwwdovepresscom Dovepress International Journal Nanomedicine 201712 Dovepress Gatifloxacin NPs CNS tuberculosis cryoprotectant FlexiDry MP FTS Systems Stone Ridge NY USA Rhloaded PLGApolysorbate 80 NPs prepared nanoprecipitation method indicated previously 12 mL 05 PVA 05 polysorbate 80 external phase NPR2 Table 1 All NP formulations prepared triplicate Rhloaded PLGALabrafil NPs prepared protocol incorporating 35 mg Labrafil inner phase emulsion NPR3 When Labrafil incorporated desiccation process performed vacuum Gatifloxacinloaded PLGA NPs Gatloaded PLGA NPs Gatloaded PLGApolysorbate 80 NPs Gatloaded PLGALabrafil NPs prepared procedure incorporating 5 mg Gat inner phase Table 1 shows different formulations prepared In cases blank NPs prepared Morphology size NPs Shape surface morphology NPs analyzed scanning electron microscopy SEM JEM 6335F JEOL Tokyo Japan Samples coated layer colloidal gold applied cathodic vacuum evaporator observation SEM 20 kV Mean diameter size distribution NPs determined Zetatrac Ultra Microtac Montgomeryville PA USA 25C NPs suspended water The average diameter expressed volume diameter size distribution graphically represented volumedistribution curves These measurements performed formula tions prepared Process yield encapsulation efficiency Process yield calculated ratio total weight NPs obtained total weight drug polymer excipients added Gatencapsulation efficiency EE determined weighing 10 mg NPs dissolved 1 mL Cl2CH2 Then ethanol 15 mL added centrifuged 5 minutes 5000 rpm This proce dure repeated times extract Gat completely Then samples filtered 045 µm filters Gat content formulation quantified highperformance liquid chromatography HPLC For HPLC quantification instrumentation Series 200 chromatograph equipped 1740 HP 235C diodearray detector PerkinElmer Waltham MA USA 295 nm The HPLC utilized C18 Mediterranea Sea chromatographic column 2504 mm particle size 5 µm Teknokroma Barcelona Spain The mobile phase consisted acetonitrilewater 8020 vv 03 trimethylamine The pH adjusted 33 phosphoric acid The flow rate 1 mLmin Data collected processed TurboChrom Navigator version 611 PerkinElmer All analyses performed 25C05C determination carried triplicate EE Gat calculated ratio drug content NPs drug preparation To calculate EE excipients included polymeric matrix taken account In case polysorbate deter mined theoretical polysorbate 80 present internal phase remain formulation From solubility acetone 10 g100 mL water 5 g100 mL wateracetone partition coefficient estimated Kr0515 Rh EE determined adding 5 mg NPs mulation 6 mL Cl2CH The solution centrifuged 20 minutes 10000 rpm supernatant filtered 045 µm filters appropriated dilutions Cl2CH2 Rh analyzed spectroscopy fluorescence λex 351 nm λem 578 nm Varian Cary Eclipse fluorescence spectrophotom eter Agilent Technologies Santa Clara CA USA ζPotential ζPotential measurements obtained laserDoppler anemometry Zetasizer Malvern Instruments Malvern UK Measurements carried 25C aqueous solution effective voltage 150 V Briefly 5 mg lyophilized NP formulation weighed placed flask diluted 50 mL distilled water kept sonicator 5 minutes The aqueous dispersions NPs introduced capillary cell Malvern Instruments ζpotential measurements All formulations analyzed triplicate In vitro release studies In vitro release Gat NPs carried heated bath WB22 Memmert GmbH Schwabach Germany 37C02C constant shaking 100 rpm NPs 10 mg suspended 3 mL phosphatebuffered saline PBS pH 74 At regular time intervals 25 mL PBS withdrawn centrifuged 15000 rpm filtered 045 nm filters Gat content quantified HPLC method described Formulations NPG1NPG3 analyzed triplicate International Journal Nanomedicine 201712 submit manuscript wwwdovepresscom Dovepress 1961 Marcianes et al Dovepress Biodistribution rhodamine NPs Male Wistar rats Harlan Laboratories Indianapolis IN USA weighing 250300 g housed maintained room 22C2C automatic light cycles 12hour lightdark food water consumption ad libitum All animal procedures approved ethics com mittee Universidad Complutense Madrid Spain conducted according European Community Council Directive 01063UE Efforts minimize number animals suffering The following animal groups established study group 1 G1 control group animals n6 receiv ing Rh 13 mgkg saline group 2 G2 animals n6 receiving equivalent 13 mgkg Rh encapsulated formulation NPR1 suspended saline group 3 G3 animals n6 receiving equivalent 13 mgkg Rh encapsulated formulation NPR2 prepared 05 polysorbate 80 suspended saline group 4 G4 animals n6 receiving equivalent 13 mgkg Rh encapsulated formulation NPR3 prepared Labrafil suspended saline Animals anesthetized isoflurane injection corresponding formulation 05 mL performed tail vein means 25 G syringe At 30 60 minutes administration animals killed brains lungs livers removed In vivo evaluation NPs transport BBB Rat brain coronal sections 25 µm thickness obtained means cryostat CM1850 Leica Microsystems Wetzlar Germany Brain sections mounted Superfrost Plus glass slides Thermo Fisher Scientific Waltham MA USA stored 80C analysis For visualization brain sections fixed 10 minutes PBS pH 74 containing 4 formaldehyde After washes PBS pH 74 1 minute slides rinsed solution containing 00001 DAPI Sigma Aldrich forms fluorescent complexes natural doublestranded DNA Afterward slices dehydrated submerging increasing concentrations ethanol 70 95 100 1 minute Once dehydrated slides rinsed xylene 2 minutes Finally DPX mounting medium SigmaAldrich poured brain sections coverslipped Samples kept horizontally dark 24 hours harden mounting medium manipulation Brain sections observed fluorescence micros copy IX51 Olympus Corporation Tokyo Japan For sections rat region cerebral cortex hippocampus 40 sections region rat analyzed All images captured condi tions exposure time gain Tetramethylrhodamine isothiocyanate bluecyan filters visualize Rh DAPI labeling respectively Brain slices analyzed 460 nm excitation wavelength 500 nm emission fluo rescence The images digitally captured processed ImageJ software version 146r Quantification rhodamine fluorescence brain The fluorescence intensity Rh encapsulated NPs analyzed confocal microscopy Olympus IX51 540 nm excitation wavelength 570 nm emission fluo rescence All micrographs obtained confocal microscopy analyzed ImageJ version 147 Rh quantifica tion Data expressed averages fluorescence intensity measured image Biodistribution rhodamine rhodamine NPs lungs liver Lungs livers weighed homogenized known volumes CH2Cl2 disrupt NPs order extract Rh content After 4 hours room temperature extracts centrifuged 2000 g 10 minutes Rh fluorescence intensity measured Varian Cary Eclipse λex 351 nm λem 578 nm The extraction efficiency Rh organs determined spiked known amounts Rh Extracts Rhfree tissues control autofluorescence body tissue The Rh distributed tissues calculated based standard curves expressed Rh gram tissue Data mean standard deviation analyzed oneway analysis variance followed Students ttest Differences considered significant P005 Cytotoxicity studies In order study neuronal viability DAPIlabeled cells level hippocampus quantified administra tion Rh NP formulations DAPI fluorescent dye selectively binds doublestranded DNA survival cells Brain sections observed fluorescence micros copy Olympus IX51 neuronal cells analyzed ImageJ version 146r The number neuronal cells determined 30 60 minutes formulations Data mean number neuronal cells standard deviation 1962 submit manuscript wwwdovepresscom Dovepress International Journal Nanomedicine 201712 Dovepress Gatifloxacin NPs CNS tuberculosis analyzed oneway analysis variance followed Students ttest Differences considered significant P005 Results discussion The main objective work develop nano carrier Gat consisting Gatloaded PLGA NPs destined facilitate increase passage drug BBB order improve treatment brain TB The BBB key barrier limits access drugs brain For firstly developed Rhloaded NPs functionalized incorporation different surfactants order characterize passage BBB select appropriate formulation point view As surface modifiers polysorbate 80 Labrafil Table 1 Rh fluorescent dye utilized quantify biodistribution NPs It widely reduced ability cross BBB given intravenously16 Mean particle sizes Rh NPs 234843 nm 194957 nm 237811 nm formulations NPR1 NPR2 NPR3 respectively Table 2 Lower particle sizes obtained formulations prepared polysor bate 80 The reduction particle size addition polysorbate 80 accordance work reduction particle size obtained polysorbate 80 preparation PLGA NPs17 With regard EE mean values 55304 formulation NPR1 51303 formulation NPR2 60904 formu lation NPR3 Table 2 corresponded drug payloads 263004 mg 242002 mg 272002 mg100 mg NPs respectively Brain biodistribution studies Rhloaded NPs formu lations NPR1 NPR2 NPR3 Rh solution performed male Wistar rats For analysis brain slices cortex hippocamppus carried confocal Table 2 Characteristics nanoparticle formulations prepared Formulation Mean particle size standard deviation nm ζPotential standard deviation mV Encapsulation efficiency standard deviation NPr1 NPr2 NPr3 NPB1 NPB2 NPB3 NPg1 NPg2 NPg3 234843 194957 237811 150551 98996 156361 1766116 176529 182925 2313 19111 1731 18604 20111 19308 55304 51303 60904 34101 28202 10411 microscopy 30 60 min intensity fluores cence measured Table 3 As example Figure 1 shows microphograps corresponding brain samples cortex After administration Rh saline Figure 1A 1E low fluorescence intensity obtained 30 60 min indicating low ability Rh cross BBB These results agreement studies Rh study passage drugs BBB1819 Increased fluorescence intensity NPR1 NPR2 NPR3 observed cortex hippocamppus Table 3 confirming access CNS On hand fluorescence intensity decreased 60 minutes Rh given solution nonfunctionalized Rhloaded NPs NPR1 This reduction pronounced cortex decrease fluores cence 60 resulted Rh saline This decrease explained fact Rh substrate Pgp ejected BBB4 At 60 minutes highest fluorescence intensity values hippocampus cortex obtained functionalized NPs NPR2 NPR3 compared nonfunctionalized NPs NPR1 indicating formulations increased passage BBB Table 3 This attributed potential effects nonionic surfactants Tween Pluronic dαtocopheryl PEG Brij reducing cel lular drug efflux4 Moreover comparison functionalized NPs NPR2 NPR3 Rh solution showed fluorescence intensity cortex tenfold higher With regard formulation NPR2 fluorescence intensity obtained threefold higher exhibited formulation NPR1 This significant increase attributed release Rh NPs presence Rh inside BBB It demonstrated functionalization NPs polysorbate 80 enables transport nanocarriers BBB passage preferentially medi ated adsorption ApoA1 ApoB andor ApoE surfaces described polysorbate 80coated polybutylcy anoacrylate NPs22 These apolipoproteins mediate interac tion LDL receptors receptors kind BBB followed aforementioned brainuptake processes endocytosis followed transcytosis11 Another study showed polysorbate 80coated NPs taken human bovine endothelial cells rapidly greater extent conventional nanocarriers23 On hand authors indicated NPs coated hydrophilic surfactants interact ApoE lowering ability cross BBB24 With Labrafil International Journal Nanomedicine 201712 submit manuscript wwwdovepresscom Dovepress 1963 Marcianes et al Table 3 Brain biodistribution rhodamine solution rhodamineloaded nanoparticles Formulation Fluorescence intensity mean standard deviation Rhodamine solution NPr1 NPr2 NPr3 30 minutes Hippocampus 1377139 1995169 2972105 2961245 Cortex 1078111 1699348 1756342 1809211 60 minutes Hippocampus 979157 1031183 3026213 2135171 Dovepress Cortex 313153 922205 3136195 2625283 slightly hydrophobic surfactant polysorbate 80 NPs able cross BBB mechanism involved unknown spite known ability increase permeability biological membranes25 Our results dem onstrate surface modification polymer polysorbate 80 Labrafil facilitates access NPs CNS raising NP formulations developed improve access brain active ingredients exhibit limited passage PLGA polymer widely preparation microparticles nanosystems biodegradable biocompatible properties However toxic effects cells tissues frequently related administra tion polymeric NPs26 When given intravenously NPs cid36 cid37 cid38 cid39 cid40 cid41 cid42 cid43 Figure 1 Confocal microscopy images cerebral cortex Notes control A NPr1 B NPr2 C NPr3 D obtained 30 minutes control E NPr1 F NPr2 G NPr3 H obtained 60 minutes interact proteins molecules present blood tissues leading structure composition thickness varies depending chemical properties surface used27 Research suggested involve ment NPs production reactive oxygen species inflammatory processes affecting BBB microglia present brain parenchyma28 The small size NPs appears increase reactivity influences physicochemical properties interaction envi ronment direct relationship nanometric particle sizes high surfacevolume ratios For cytotoxicity studies formulations prepared carried Figure 2 shows hippocampus micro photographs obtained 30 60 minutes control solution Rh solution NP formulations tested NPR1 NPR2 NPR3 No statistically significant differ ences cell viability formulations These results experimental conditions number surviving neurons significantly affected functionalization NPs polysorbate 80 Labrafil Biodistribution NPs liver lungs expressed Rh gram tissue order com pensate animal variability Figure 3 At times assayed 30 60 minutes Rh concentrations lungs higher livers formulations NPR1 NPR2 NPR3 At 30 minutes Rh concentrations lungs threefold higher livers formulation NPR2 coated polysorbate 80 1293 vs 431 µg Rhg tissue This greater biodistribu tion NPs lungs required target M tuberculosis mainly present airways explained fact polysorbate 80 ionic surfactant hydrophilic characteristics prevents opsonization identification mononuclear phagocyte For formulations NPR1 NPR3 ratio 21 24fold respectively After 60 minutes Rh concentrations markedly decreased organs formulations assayed Figure 3 In summary 1964 submit manuscript wwwdovepresscom Dovepress International Journal Nanomedicine 201712 Dovepress rA l n o r u e N e b m u n s l l e c 3000 2500 2000 1500 1000 500 0 B b c d Rhodamine solution NPR1 NPR2 NPR3 e f g h Figure 2 Neuronal cells corresponding control treated animal groups A Hippocampus sections obtained control treatment groups B images obtained 30 minutes control group treated Rhodamine solution group trated formulation NPR1 b group treated formulation NPR2 c group treated formulation NPR3 d Imaged obtained 60 minutes control group e group treated formulation NPR1 f group treated formulation NPR2 g group treated formulation NPR3 h 60 minutes concentrations Rh decreased organs increased brain Table 3 This attributed increased passage NPs BBB inhibiting effect caused surfactants Pgp efflux Gatifloxacin NPs CNS tuberculosis distinguish For purpose Gat loaded PLGA NPs prepared surface modifier NPG1 surfactants polysorbate 80 NPG2 Labrafil NPG3 increase Gat access brain Table 1 Gatloaded PLGA NPs characterized terms morphology size ζpotential EE vitro release SEM images Gatloaded PLGA NPs Figure 4 blank NPs data shown revealed formulations spherical Previous studies shown spherical particles moving vessel deviate streamline motion experiencing external force case aspheric particles segregation occur29 Mean particle sizes formulations NPG1 NPG2 NPG3 1766116 nm 176529 nm 182925 nm respectively Span values Gatloaded PLGA NPs ranged 07 107 PI 038 reflecting slight polydispersion particle sizes indicates method employed prepara tion NPs results monodisperse distributions This particularly important considering passage NPs BBB Studies revealed NPs coated polysorbate 80 average particle size 250 nm able cross BBB2021 For formulations ζpotential negative probably presence ionized carboxyl groups surface NPs For blank NPs NPB1 value 2313 mV measured similar described literature NPs prepared Resomer 502 PLGA Table 230 This value decreased significantly NPs functionalized polysorbate 80 NPB2 19111 mV Labrafil NPB3 1731 mV This modification ζpotential confirms presence agent surfactant polymeric matrix Encapsulation Gat significantly diminished ζpotential compared blank NPs 2313 mV With regard ζpotential presence Gat showed higher influence surfactants Research indicated positive ζpotential values improve passage NPs BBB exhibiting stronger immune response31 Furthermore high negative ζpotential values prevent aggregation phenomena It reported stable nanosuspension mainly stabilized electrostatic repulsion exhibited ζpotential values near 30 mV facilitating admnistration32 In case assumed NP formulations probably remained long bloodstream able cross BBB Taking consideration functionalized formulations NPR2 NPR3 showed improved biodis tribution brain studies carried order For formulations prepared mean process yield ranged 43145 66121 EE values 341012 28202 10411 International Journal Nanomedicine 201712 submit manuscript wwwdovepresscom Dovepress 1965 Marcianes et al Dovepress cid36 cid72 cid88 cid86 cid86 cid76 cid87 cid3 cid74 cid18 cid22 cid21 cid20 cid75 cid53 cid74 cid151 cid3 cid20cid27 cid20cid25 cid20cid23 cid20cid21 cid20cid19 cid27 cid25 cid23 cid21 cid19 cid47cid76cid89cid72cid85 cid47cid88cid81cid74cid86 cid37 cid72 cid88 cid86 cid86 cid76 cid87 cid3 cid74 cid18 cid22 cid21 cid20 cid75 cid53 cid74 cid151 cid3 cid26 cid25 cid24 cid23 cid22 cid21 cid20 cid19 cid47cid76cid89cid72cid85 cid47cid88cid81cid74cid86 cid49cid51cid53cid20 cid49cid51cid53cid21 cid49cid51cid53cid22 Figure 3 Mean concentrations rhodamine Rh standard deviation Notes In liver lungs 30 minutes A 60 minutes B administration RhPLGA NPs NPR1 RhPLGA NPs NPR2 RhPLGA NPs prepared polysorbate 80 NPR3 RhPLGA NPs prepared Labrafil Abbreviations PLGA polylacticcoglycolic acid NPs nanoparticles cid36 cid37 cid38 cid49cid51cid42cid20 cid72 cid89 cid79 cid76 cid87 cid68 cid88 cid80 cid88 cid70 cid81 cid68 cid72 cid48 cid3 cid49cid82cid81cid72 cid54cid40cid44 cid24cid17cid19cid3cid78cid57 cid238cid20cid19cid15cid19cid19cid19 cid20cid3cid151cid80 cid58cid39cid3cid20cid24cid17cid21cid3cid81cid80 cid49cid51cid42cid21 cid72 cid89 cid79 cid76 cid87 cid68 cid88 cid80 cid88 cid70 cid81 cid68 cid72 cid48 cid3 cid12 cid8 cid11 cid3 cid55 cid36 cid42 cid72 cid86 cid68 cid72 cid3 cid79 cid72 cid85 cid20cid19cid19 cid27cid19 cid25cid19 cid23cid19 cid21cid19 cid19 cid12 cid8 cid11 cid3 cid55 cid36 cid42 cid72 cid86 cid68 cid72 cid3 cid79 cid72 cid85 cid20cid19cid19 cid27cid19 cid25cid19 cid23cid19 cid21cid19 cid19 cid49cid51cid42cid20 cid19 cid20cid19 cid21cid19 cid22cid19 cid55cid76cid80cid72cid3cid11cid75cid82cid88cid85cid86cid12 cid23cid19 cid24cid19 cid49cid51cid42cid21 cid49cid82cid81cid72 cid54cid40cid44 cid24cid17cid19cid3cid78cid57 cid238cid20cid19cid15cid19cid19cid19 cid20cid3cid151cid80 cid58cid39cid3cid20cid24cid17cid21cid3cid81cid80 cid19 cid20cid19 cid21cid19 cid22cid19 cid55cid76cid80cid72cid3cid11cid75cid82cid88cid85cid86cid12 cid23cid19 cid24cid19 cid49cid51cid42cid22 cid72 cid89 cid76 cid87 cid68 cid79 cid88 cid80 cid88 cid70 cid3 cid81 cid68 cid72 cid48 cid12 cid8 cid11 cid3 cid55 cid36 cid42 cid3 cid72 cid86 cid68 cid72 cid79 cid72 cid85 cid20cid19cid19 cid27cid19 cid25cid19 cid23cid19 cid21cid19 cid19 cid49cid51cid42cid22 cid49cid82cid81cid72 cid54cid40cid44 cid24cid17cid19cid3cid78cid57 cid238cid20cid19cid15cid19cid19cid19 cid20cid3cid151cid80 cid58cid39cid3cid20cid24cid17cid21cid3cid81cid80 cid19 cid20cid19 cid21cid19 cid22cid19 cid55cid76cid80cid72cid3cid11cid75cid82cid88cid85cid86cid12 cid23cid19 cid24cid19 cid3 Figure 4 Scanning electron microscopy images mean vitro release profiles Gat Notes From gatloaded Plga NPs NPg1 A Gatloaded PLGA NPs prepared polysorbate 80 NPG2 B Gatloaded PLGA NPs prepared Labrafil NPg3 C Abbreviations Gat gatifloxacin PLGA polylacticcoglycolic acid NPs nanoparticles 1966 submit manuscript wwwdovepresscom Dovepress International Journal Nanomedicine 201712 Dovepress Gatifloxacin NPs CNS tuberculosis formulations NPG1 NPG2 NPG3 respectively Table 2 Gat compound low solubility nonpolar solvents exhibiting low affinity polymeric matrix Moreover incorporation Labrafil significantly reduces EE probably related lower solubility drug presence surfactant In vitro release Gat NPs studied normal blood pH 74 Gat release formulations exhibited biphasic profile rapid release occurred 10 hours Figure 4 This rapid release explained physicochemical characteristics Gat exhibits greater affinity PBS medium polymer matrix small particle sizes obtained Moreover high surface areavolume ratio favors rapid release3334 Though rapid release Gat provides short temporal control drug release main purpose delivery reach site action cross BBB purpose reasonably achieved taking consideration rapid access NPs brain Considering 30 minutes 80 Gat encapsulated NPs exert therapeutic action CNS Conclusion PLGA NPs prepared surfactants Labrafil polysorbate 80 showed improved passage BBB PLGA NPs resulting adequate carriers deliver drugs CNS EE Gat PLGA NPs functionalized Labrafil low For reason nanosystem adequate encapsulation drug substances high affinity polymeric matrix However Gatloaded PLGA NPs functionalized polysorbate 80 presented higher EE adequate size distribution promising drugdelivery treat CNS TB Acknowledgments This work partially supported Complutense University UCM research group 910939 The authors thank Centro Microscopía Electrónica Luis Bru CAI UCM Unidad Cartografía Cerebral Instituto Pluridisciplinar UCM technical assistance Disclosure The authors report conflicts work References 1 Kulchavenya E Extrapulmonary tuberculosis statistical reports accurate Ther Adv Infect Dis 2014226170 2 Abbott NJ Patabendige AA Dolman DE Yusof SR Begley DJ Structure function bloodbrain barrier Neurobiol Dis 2010 3711325 3 World Health Organization Global Tuberculosis Report Geneva WHO 2015 4 Chen HH Huang WC Chiang WH et al pHresponsive therapeutic solid lipid nanoparticles reducing Pglycoproteinmediated drug efflux multidrug resistant cancer cells Int J Nanomedicine 201510 50355048 5 Saravolatz LD Leggett J Gatifloxacin gemifloxacin moxifloxa cin role 3 newer fluoroquinolones Clin Infect Dis 2003379 12101215 6 Thwaites GE Bhavnani SM Chau TT et al Randomized phar macokinetic pharmacodynamic comparison fluoroquino lones tuberculous meningitis Antimicrob Agents Chemother 201155732443253 7 Zhang Z Lu J Wang Y Pang Y Zhao Y Prevalence molecular characterization fluoroquinoloneresistant Mycobacterium tuber culosis isolates China Antimicrob Agents Chemother 2014581 364369 8 Kwatra D Vadlapatla RK Vadlapudi AD Pal D Mitra AK Epide miology antimicrobial resistance staphylococci isolated different infectious diseases Braz J Microbiol 2010412333344 9 Hillaireau H Couvreu P Nanocarriers entry cell relevance drug delivery cell Mol Life Sci 2009601728732896 10 Suchlfart S Gelperina S Kreuter J Transport drug bloodbrain barrier nanoparticles J Control Release 20121612 264273 11 Kreuter J Mechanism polymeric nanoparticlesbased drug transport bloodbrain barrier BBB J Microencapsul 2013301 4954 12 Tosi G Costantino L Rivasi F et al Targeting central nervous vivo experiments peptidederivatized nanoparticles loaded loperamide rhodamine123 J Control Release 2007 122119 13 Kreuter J Drug delivery central nervous polymeric nano particles know Adv Drug Deliv Rev 201471214 14 Zhang Q Li F Combating Pglycoproteinmediated multidrug resis tance therapeutic nanoparticles Curr Pharm Des 20131937 66556666 15 Vera M Barcia E Negro S et al New celecoxib multiparticulate sys tems improve glioblastoma treatment Int J Pharm 201447312 518527 16 Fazil M Muhammad S Haque S et al Development evaluation rivastigmine loaded chitosan nanoparticles brain targeting Eur J Pharm Sci 2012471615 17 Kohei T Sahori F Hiromitsu Y Yoshiaki K Hybridmodified polyDL lactidecoglycolide nanospheres novel cellular drug delivery Int J Pharm 201039212311313 18 Martins S Tho I Reimold I et al Brain delivery camptothecin means solid lipid nanoparticles formulation design vitro vivo studies Int J Pharm 2012439124962 19 Tosi G Vergoni AV Ruozi B et al Sialic acid glycopeptides conjugated PLGA nanoparticles central nervous target ing vivo pharmacological evidence biodistribution J Control Release 201014514957 20 Kreuter J Ramge P Petrov V et al Direct evidence polysorbate 80coated polybutylcyanoacrylate nanoparticles deliver drugs CNS specific mechanisms requiring prior binding drug nanoparticles Pharm Res 2003203409416 21 Alyautdin RN Reichel A Löbenberg R Ramge P Kreuter J Begley DJ Interaction polybutylcyanoacrylate nanoparticles blood brain barrier vivo vitro J Drug Target 200193209221 22 Ramge P Unger RE Oltrogge JB et al Polysorbate80 coating enhances uptake polybutylcyanoacrylate PBCAnanoparticles human bovine primary brain capillary endothelial cells Eur J Neurosci 200012619311940 International Journal Nanomedicine 201712 submit manuscript wwwdovepresscom Dovepress 1967 Marcianes et al Dovepress 23 Sempf K Arrey T Gelperina S et al Adsorption plasma proteins uncoated PLGA nanoparticles Eur J Pharm Biopharm 2013851 5360 29 Jose S Sowwmya S Cinu TA Aleykutty NA Thomas S Souto EB Surface modified PLGA nanoparticles brain targeting bacosideA Eur J Pharm Sci 2014632935 24 Kreuter J Petrov VE Kharkevich DA Alyautdin RN Influence type surfactant analgesic effects induced peptide dalargin delivery bloodbrain barrier surfactant coated nanoparticles J Control Release 19974918187 25 Karamanidou T Karidi K Bourganis V Kontonikola K Kammona O Kiparissides C Effective incorporation insulin mucus permeating selfnanoemulsifying drug delivery systems Eur J Pharm Biopharm 201595Pt A223229 26 Kolter M Ott M Hauer C Reimold I Fricker G Nanotoxicity polyn butylcyanoacrylate nanoparticles bloodbrain barrier human blood vivo J Control Release 201519710165179 27 Monopoli MP Aberg C Salvati A Dawson KA Biomolecular coronas provide biological identity nanosized materials Nat Nanotechnol 2012712779786 28 Sharma HS Sharma A Neurotoxicity engineered nanoparticles metals CNS Neurol Disord Drug Targets 20121116580 30 Fonseca C Simoes S Gaspar R Paclitaxelloaded PLGA nanoparticles preparation physicochemical characterization vitro antitumoral activity J Control Release 2002832273286 31 SalvadorMorales C Zhang L Langer R Farokhzad OC Immuno compatibility properties lipidpolymer hybrid nanoparticles heterogeneous surface functional groups Biomaterials 20093012 22312240 32 Müller RH Jacobs C Kayser O Nanosuspensions particulate drug formulations therapy rationale development expect future Adv Drug Deliv Rev 2001471319 33 Bawarski N Chidlowsky E Bharali DJ Mousa SA Emerging nanop harmaceuticals Nanomedicine 200844273282 34 Lu XF Shi YF Lv HL Fu YY Ma D Xue W Preparation char acterization molecularly imprinted polyhydroxyethyl methacrylate microspheres sustained release gatifloxacin J Mater Sci Mater Med 201425614611469 International Journal Nanomedicine Publish work journal The International Journal Nanomedicine international peer reviewed journal focusing application nanotechnology diagnostics therapeutics drug delivery systems biomedical field This journal indexed PubMed Central MedLine CAS SciSearch Current ContentsClinical Medicine Dovepress Journal Citation ReportsScience Edition EMBase Scopus Elsevier Bibliographic databases The manuscript management completely online includes quick fair peerreview easy use Visit httpwwwdovepresscom testimonialsphp read real quotes published authors Submit manuscript httpwwwdovepresscominternationaljournalofnanomedicinejournal 1968 submit manuscript wwwdovepresscom Dovepress International Journal Nanomedicine 201712